Clinical Trials › NCT07299019
RecruitingPhase 3
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Sponsored by Zenas BioPharma (USA), LLC
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 990
Target enrollment
1
U.S. states
Mar 2026
Start date
Jul 2030
Expected completion
Interventions / Treatments
OrelabrutinibPlacebo
Conditions studied
Secondary Progressive Multiple Sclerosis
Where this trial is running (1 site)
Florida1 site
Maitland
MS centers in Florida
Compare treatment centers near a trial site by center type, providers and trials.
View Florida centersMore Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.